Roshni Patel
ATF4 as a Prognostic Marker and Modulator of Glutamine Metabolism in Estrogen Receptor Positive Breast Cancer
Patel, Roshni; Alfarsi, Lutfi H.; El-Ansari, Rokaya; Masisi, Brendah K.; Erkan, Busra; Fakroun, Ali; Ellis, Ian O.; Rakha, Emad A.; Green, Andrew R.
Authors
Lutfi H. Alfarsi
Rokaya El-Ansari
Brendah K. Masisi
Busra Erkan
Ali Fakroun
Ian O. Ellis
EMAD RAKHA Emad.Rakha@nottingham.ac.uk
Professor of Breast Cancer Pathology
ANDREW GREEN ANDREW.GREEN@NOTTINGHAM.AC.UK
Associate Professor
Abstract
Purpose: ATF4, a stress-responsive transcription factor that upregulates adaptive genes, is a potential prognostic marker and modulator of glutamine metabolism in breast cancer. However, its exact role remains to be elucidated.
Methods: ATF4 expression was evaluated at genomic and transcriptomic levels using METABRIC (n=1980), GeneMiner (n=4712) and KM-Plotter datasets. Proteomic expression was assessed via immunohistochemistry (n=2225) in the Nottingham Primary Breast Cancer Series. ATF4 genomic copy number (CN) variation and mRNA/protein in association with clinicopathological parameters, amino acid transporters (AATs), and patient outcome was investigated.
Results:
Genomic, transcriptomic, and proteomic overexpression of ATF4 was associated with more aggressive ER-negative tumours. ATF4 mRNA and protein expression were significantly associated with increased expression of glutamine related AATs including SLC1A5 (p<0.01) and SLC7A11 (p<0.02). High ATF4 and SLC1A5 protein expression was significantly associated with shorter breast cancer-specific survival (p<0.01), especially in ER+ tumours (p<0.01), while high ATF4 and SLC7A11 protein expression was associated with shorter survival (p<0.01).
Conclusion: These findings suggest a complex interplay between ATF4 and AATs in breast cancer biology and underscore the potential role for ATF4 as a prognostic marker in ER+ breast cancer, offering a unique opportunity for risk stratification and personalised treatment strategies.
Citation
Patel, R., Alfarsi, L. H., El-Ansari, R., Masisi, B. K., Erkan, B., Fakroun, A., …Green, A. R. (in press). ATF4 as a Prognostic Marker and Modulator of Glutamine Metabolism in Estrogen Receptor Positive Breast Cancer. Pathobiology, https://doi.org/10.1159/000539564
Journal Article Type | Article |
---|---|
Acceptance Date | May 25, 2024 |
Online Publication Date | Jun 11, 2024 |
Deposit Date | May 28, 2024 |
Publicly Available Date | Jun 11, 2024 |
Journal | Pathobiology |
Print ISSN | 1015-2008 |
Electronic ISSN | 1423-0291 |
Publisher | Karger Publishers |
Peer Reviewed | Peer Reviewed |
DOI | https://doi.org/10.1159/000539564 |
Keywords | activating-transcription factor 4; breast cancer; glutamine metabolism; amino-acid transporters 2 |
Public URL | https://nottingham-repository.worktribe.com/output/35429989 |
Publisher URL | https://karger.com/pat/article/doi/10.1159/000539564/909095/ATF4-as-a-Prognostic-Marker-and-Modulator-of |
Files
ATF4 V20 Manuscript
(4.1 Mb)
PDF
Licence
https://creativecommons.org/licenses/by/4.0/
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
The role of the ALKBH5 RNA demethylase in invasive breast cancer
(2024)
Journal Article
Stromal lymphocytes are associated with upgrade of B3 breast lesions
(2024)
Journal Article
The characteristics and prognostic significance of histone H1 expression in breast cancer
(2024)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search